2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Cell Expansion, Emerging Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

4150 Autologous stem cell transplantation enhances CAR T-cell efficacy and suppresses CD19-negative lymphoma escape through cDC1-dependent epitope spreading

Xiaoying Zhang, Jia Wei, MD, PhD2, Yang Cao, MD3, Jue Wang4, Yicheng Zhang5
1 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technolog, Wuhan, China
2 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technolog, Wuhan, China
3 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technolog, Wuhan, China
4 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technolog, Wuhan, China
5 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technolog, Wuhan, China

Background:

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed/refractory diffuse large B-cell lymphoma, yet two-thirds of patients remain at risk of relapse or progression, with CD19-negative escape representing an important mechanism of resistance. Autologous stem cell transplantation (ASCT) followed by CAR T-cell infusion can produce durable remissions, suggesting that immune reconstitution may recruit antitumor responses. Conventional type 1 dendritic cells (cDC1s) specialize in cross-presenting tumor-derived antigens and priming endogenous T cells, but their contribution to sequential therapy remains unknown. We therefore sought to determine whether cDC1-dependent epitope spreading links ASCT-mediated immune reconstitution to the control of CD19-negative lymphoma.

Methods:

We established two immunocompetent syngeneic murine lymphoma models: CAR T-cell monotherapy (CAR T-only) and ASCT combined with CAR T-cell therapy (Sequential). Tumor growth and survival were monitored. Single-cell RNA sequencing and paired T-cell receptor sequencing (scRNA/TCR-seq) profiled the intratumoral immune landscape, and ELISPOT assays quantified endogenous T-cell reactivity. To test CAR-independent epitope spreading, mice bearing subcutaneous CD19-positive tumors in the left flank received the assigned treatment before contralateral challenge with CD19-negative cells. The requirement for cDC1 was examined by repeating the treatment comparison in Batf3−/− mice.

Results:

Sequential treatment conferred superior tumor control (P=0.006) and extended survival relative to CAR T-cell therapy alone. Single-cell transcriptomic profiling revealed broad remodeling of the tumor immune microenvironment, with reduced regulatory T cells, myeloid-derived suppressor cells, and Isg15-high macrophages, coupled with increased intratumoral cDC1 abundance and activation. cDC1s from Sequential tumors acquired a coordinated antigen-presentation state characterized by predominant upregulation of H-2 class II molecules, concurrent induction of H-2 class I molecules, and high expression of the MHC class II invariant chain Cd74. Gene-set enrichment revealed a shift from the interferon-response program that predominated after CAR T-cell therapy alone toward programs associated with antigen processing and presentation, granulocyte migration, and IL-1 signaling after Sequential treatment.

Sequential treatment exhibited a distinct distribution of T cell subsets, characterized by an increased proportion of CD8+ naïve T cells, reduced expression of CD8+ T cell exhaustion markers, and expansion of resident subsets (Cxcr6+ CD4+ T cells). Paired TCR-seq revealed that Sequential treatment selected or generated T cells with longer CDR3 regions, exhibited a bias toward specific paired TRAV-TRBV gene usage and increased overall TCR diversity, thereby enhancing antigen epitope spreading. Within the cytotoxic CD8+ T-cell compartment, low-expansion clonotypes were enriched and exhibited higher cytotoxicity and lower exhaustion scores, consistent with a broader, highly functional endogenous response. ELISPOT assays corroborated increased endogenous T-cell reactivity. Together, these findings demonstrate that Sequential treatment broadens the endogenous TCR repertoire and promotes epitope spreading.

Following contralateral challenge with CD19-negative cells, mice in the CAR T-only group developed progressive tumors, with a mean volume of approximately 150 mm³ on day 10, whereas no palpable lesions were detected in the Sequential group on day 10 (P=0.013). In Batf3−/− mice, Sequential treatment no longer conferred superior tumor control over CAR T-cell therapy alone (P=0.127), supporting a requirement for Batf3-dependent cDC1s in the control of CD19-negative disease.

Conclusions:

ASCT reprograms the tumor immune microenvironment to favor cDC1 accumulation and coordinated antigen presentation, thereby expanding a diverse, highly functional, and less exhausted endogenous T-cell repertoire capable of restraining CD19-negative lymphoma. The loss of therapeutic benefit in Batf3−/− mice identifies cDC1-dependent epitope spreading as a key mechanism linking ASCT-mediated immune reconstitution to durable CAR T-cell activity. These findings highlight cDC1s as central orchestrators of CAR-independent antitumor immunity and provide a mechanistic rationale for ASCT-based strategies to overcome antigen escape.

Xiaoying Zhang: No relevant conflicts of interest to declare.